## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1616

AUKUNURU ET AL.

Examiner: Basquill, Sean M

INTERNATIONAL APPLICATION NO: PCT/EP03/08005

FILED: 22 JULY 2003

U.S. APPLICATION NO: 10/521,946

35 USC §371 DATE: 5 JANUARY 2006

FOR: OPHTHALMIC OINTMENT COMPOSITION COMPRISING A DRUG, AN OINTMENT BASE AND A SOLUBILIZING/DISPERSING AGENT

**MS: Amendment** 

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed January 21, 2005. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith. The documents cited on the form(s) PTO-1449 are in the English language, with the exception of items noted below.

Item AN (CN 1323207) is in the Chinese language and is provided with an English equivalent (Item AO; (WO 00/21528).

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Cozette M. McAvoy

Reg. No. 60,457

Attorney for Applicants

Novartis Pharmaceuticals Corp. Patents Pharma One Health Plaza, Building 101 East Hanover, NJ 07936-1080 (862) 778-9273

Date: 7th November 2008